• search
  • profileicon
  • contacticon
  • emailicon

INTELLIGENT INTEGRATION: WHY CONNECTED OSD ECOSYSTEMS ARE RESHAPING PHARMACEUTICAL MANUFACTURING

Submitted by amey.sawant on
blister x
Borja Guerra, VP Sales - ACG Engineering, delves into how the oral solid dosage manufacturing industry is being reshaped by connected machinery, advanced digital systems and integrated supplier ecosystems across the production process.

ACG brings fully integrated OSD manufacturing to Europe at Interpack 2026

Submitted by amey.sawant on

Pharmaceutical manufacturing is becoming more demanding. Rising SKU variability, tighter timelines, and growing pressure to deliver more from every investment are pushing manufacturers to rethink their production strategies and to demand more from the partners they rely on.

At Interpack 2026, ACG, the world’s most integrated provider of solid dosage solutions, will demonstrate how integrated, intelligent systems can help manufacturers build better value into their oral solid dosage (OSD) operations, with solutions designed for flexibility, consistency, and long-term performance.

Go Back

Medication adherence should be a product design priority.

Medication non-adherence is estimated to raise healthcare costs by $5,000–$52,000 per patient annually in the United States.1 It’s often treated as a patient behaviour problem. But for many elderly adults, it’s also a product design issue. Regimen complexity, swallowability and packaging design all converge to influence correct administration in real-world use. Product development should therefore evaluate patient usability as early as formulation and packaging design, rather than treating non-adherence as a downstream patient issue.
Medication non-adherence is estimated to raise healthcare costs by $5,000–$52,000 per patient annually in the United States.1 It’s often treated as a patient behaviour problem. But for many elderly adults, it’s also a product design issue. Regimen complexity, swallowability and packaging design all converge to influence correct administration in real-world use. Product development should therefore evaluate patient usability as early as formulation and packaging design, rather than treating non-adherence as a downstream patient issue.
ACG